Sanofi's quarterly profit boosted by Dupixent and newer drugs, forecast unchanged

Sanofi reported stronger-than-expected third-quarter profit, primarily driven by robust sales of its blockbuster asthma drug Dupixent, which reached 4.16 billion euros against an anticipated 4 billion euros. This strong performance mitigated a 16.8% decline in vaccine sales, attributed to lower vaccination rates and a "negative buzz" around vaccines, though total global vaccine sales of 3.36 billion euros met analyst expectations. The French pharmaceutical giant's business operating income of 4.45 billion euros also surpassed forecasts, and the company reaffirmed its full-year guidance for high-single-digit sales growth and low-double-digit earnings growth, while strategically increasing R&D and acquisitions for future diversification beyond Dupixent.

Analysis

Sanofi reported a strong third quarter, surpassing profit forecasts primarily due to the robust performance of its blockbuster asthma drug, Dupixent, which generated 4.16 billion euros against an expected 4 billion euros. This strong showing, coupled with business operating income of 4.45 billion euros (exceeding the 4.15 billion euro forecast), largely offset challenges in its vaccine division.

The company's vaccine sales declined 16.8%, impacted by pricing pressure in Germany and lower global vaccination rates, partly attributed to a "negative buzz" and "post-COVID fatigue." Sanofi's CFO noted the difficulty in forecasting future vaccine sales growth given these early-season dynamics.

Despite vaccine headwinds, Sanofi's overall U.S. sales increased 11.1% to 6.84 billion euros, demonstrating resilience from other pharmaceutical segments. The company reaffirmed its full-year guidance for high-single-digit sales growth and low-double-digit earnings growth, reflecting confidence in its diversified portfolio and strategic investments in R&D and acquisitions to drive future growth beyond Dupixent.

Key Decisions for Investors

• Monitor Dupixent's continued growth trajectory and pipeline expansion, as it remains a primary revenue driver and key to future performance.
• Assess the long-term impact of declining vaccination rates and "negative buzz" on Sanofi's vaccine segment, considering potential regulatory or public health interventions.
• Evaluate the effectiveness of Sanofi's increased R&D and M&A strategies in diversifying its portfolio and mitigating reliance on Dupixent for sustained growth.